Business Context and Reporting Period
Akebia Therapeutics, Inc. (AKBA) filed a Form 8-K on May 24, 2023, reporting the entry into a Material Definitive Agreement. The filing details a strategic partnership with MEDICE Arzneimittel Pütter GmbH & Co. KG ("Medice") regarding the development and commercialization of vadadustat.
Key Financial Metrics and Agreement Terms
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it outlines the financial structure of the new License Agreement:
- Up-Front Payment: $10 million payable to Akebia.
- Commercial Milestones: Up to $100 million in aggregate payments.
- Royalties: Tiered royalties ranging from 10% to 30% of Medice's annual net sales in the Territory.
- Territory: European Economic Area, United Kingdom, Switzerland, and Australia.
- Indication: Treatment of anemia in patients with chronic kidney disease.
Material Changes and Strategic Developments
The primary material change is the exclusive licensing of vadadustat to Medice for the specified Territory. Key strategic provisions include:
- Retained Rights: Akebia retains the right to develop vadadustat for non-dialysis patients with anemia due to chronic kidney disease within the Territory.
- Non-Dialysis Commercialization: If Akebia obtains approval for the non-dialysis indication, Medice will commercialize it. Akebia would receive 70% of the net product margin for these sales unless development costs are shared.
- Governance: A joint steering committee will be established to oversee development and commercialization.
- Supply: Akebia will supply the Licensed Product to Medice for commercial use.
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The agreement positions Akebia to monetize vadadustat in key international markets while retaining potential upside in the non-dialysis patient population. A press release issued on May 25, 2023, provides further details but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Risks and Contingencies:
- Termination: Medice may terminate the agreement for convenience with 12 months' prior written notice, exercisable after the first 12 months from the Effective Date.
- Breach: Either party may terminate for uncured material breach.
- Royalty Expiration: Royalties expire country-by-country based on patent expiration, regulatory exclusivity, or 12 years from first commercial sale, whichever is latest.
Investor Verification Checklist
- Verify the receipt and accounting treatment of the $10 million up-front payment in the upcoming Form 10-Q.
- Review the full text of the License Agreement (expected as an exhibit to the Q2 2023 10-Q) for specific definitions of "net sales" and royalty reduction circumstances.
- Monitor the progress of vadadustat development for the non-dialysis indication to assess the potential for the 70% net product margin share.
- Assess the impact of the agreement on Akebia's cash runway and future capital requirements.